Connect Biopharma (CNTB) – Investment Analysts’ Weekly Ratings Updates

A number of research firms have changed their ratings and price targets for Connect Biopharma (NASDAQ: CNTB):

• 5/26/2026 – Connect Biopharma is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $6.00 price target on the stock.
• 5/21/2026 – Connect Biopharma is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $4.00 price target on the stock.
• 5/21/2026 – Connect Biopharma is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $4.00 price target on the stock.
• 5/16/2026 – Connect Biopharma was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/4/2026 – Connect Biopharma had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 3/31/2026 – Connect Biopharma had its “buy” rating reaffirmed by BTIG Research. They now have a $10.00 price target on the stock.

Insider Activity

In related news, Director James Huang acquired 1,160,000 shares of Connect Biopharma stock in a transaction dated Tuesday, March 31st. The shares were purchased at an average price of $3.45 per share, for a total transaction of $4,002,000.00. Following the completion of the transaction, the director directly owned 13,160,000 shares in the company, valued at approximately $45,402,000. This represents a 9.67% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 22.60% of the stock is currently owned by insiders.

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.